Stichting Elisabeth-Tweesteden Ziekenhuis — Clinical Trial Site

107 Registered trials

52 Currently recruiting

Organisation

Stichting Elisabeth-Tweesteden Ziekenhuis

Location

Tilburg, Netherlands

Identifier

ORG-100031075

Address

Hilvarenbeekseweg 60, 5022 GC, Netherlands

Departments

031003: Oncology
2604:Cardiology
3706: Cardiology
5001:Pulmonology
Alimentary Tract and Metabolism
Cardiology
Department of Gastroenterology & hepatology
Department of Gastroenterology and Hepatology
Department of Medical Oncology
Department of Oncology
Department of Pulmonary Diseases
Gastroeneterology
Gastroenterology
Gastroenterology & Hepatology
Gastroenterology and hepatology
Hematology
Intensive Care
internal medecine
Internal Medicine
Internal Oncology
Interne Geneeskunde
Interne geneeskunde - Oncologie
Longgeneeskunde
Maag-, Darm- en Leverziekten
Maag-, darm,- en leverziekten / Gastroenterology and Hepatology
MDL
Medical Oncology
N/A
NA
Neurology
Neurosurgery
NL10001: Internal medicine
Oncology
Oncology-Hematology
Oncology/Hematology
Ophthalmology
Orthopedic surgery
orthopedics
Orthopedie
Pulmonary medicine
Pulmonology
Pulmonology department
Reproductive medicine and gynecology
Rheumatology
Surgery
Trialoffice Oncology-Hematology
Vascular Surgery

Clinical trials at this site (107)

Search interface

A clinical study of MK-7240 for the treatment of ulcerative colitis (MK-7240-001) Unknown

2025-523766-25-00 Ulcerative colitis 5
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
ATLAS trial Pending

2024-517233-40-00 Perianal abscess 6
A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease Pending

2025-521037-86-00 Immune system diseases 5
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending

2025-521590-13-00 Moderately to Severely Active Crohn’s Disease 5
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting

2024-518296-56-00 Crohn’s Disease 5 2025-09-29
A multi-centred, partially randomised, patient-preference trial of radical surgery versus adjuvant chemoradiotherapy after local excision fo… Recruiting

2024-517410-15-01 Rectal cancer 5 2025-01-14
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participant… Recruiting

2023-505678-14-00 Ulcerative Colitis 4 2024-08-19
A phase 2, multicenter, double-blind, two-arm study of subcutaneous RO7790121 for the treatment of subjects with moderate to severe active c… Recruiting

2023-504265-23-00 Crohn's disease 4 2023-10-23
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting

2022-500461-28-06 High-Risk Metastatic Hormone-Sensitive Prostate Cancer 5 2022-09-15
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK-2870-031) Recruiting

2024-520014-22-00 Locally advanced/metastatic urothelial carcinoma 5 2026-04-22
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Untreated, Unresectable or Metastatic Colorectal Cancer 10 2026-03-30
An induction study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease Recruiting

2025-521036-11-00 Immune system disseases 5 2026-03-23
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis Recruiting

2025-521242-26-00 Moderately to Severely Active Ulcerative Colitis 4 2025-11-27
A phase 2 study of the effectiveness of golcadomide (CC-99282) for patients with large B-cell lymphoma in the brain Recruiting

2024-517051-12-00 Relapsed primary large B-cel lymphoma of the central ne 4 2025-09-16
Total Neoadjuvant Therapy for lymph node-positive adenocarcinoma of the OESophagus and oesophagogastric junction: TNT-OES-2 trial Recruiting

2025-521158-40-00 oesophageal cancer 4 2025-09-12
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Moderate to Severely Active Ulcerative Colitis & Modera 4 2025-08-27